Dear Ms. Thambipillai:

Please refer to your Supplemental Biologics License Application (sBLA), dated June 19, 2013 received June 19, 2013, submitted under section 351(a) of the Public Health Service Act for Herceptin® (trastuzumab).

We acknowledge receipt of your amendments dated January 31, June 19, and November 14, 2013.

This Prior Approval supplemental biologics application was requested by the Agency to revise the full prescribing information of the package insert by adding “carboplatin” to the second paragraph in Section 7 DRUG INTERACTIONS.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling text for the package insert and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at
The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**FULFILLMENT OF POSTMARKETING REQUIREMENT(S)/COMMITMENT(S)**

We have received your submission dated January 31, 2013, which contains the final report for the following postmarketing commitment listed in the May 22, 2008, approval letter for sBLA 103792/5187 and 5189.

2. To perform a DDI trial in metastatic cancer patients to evaluate the impact of Herceptin on Carboplatin pharmacokinetics and to evaluate the impact of Carboplatin on Herceptin pharmacokinetics. Herceptin concentrations in the DDI trial will be compared to clinical pharmacokinetic data from clinical trials BO16348, BO15935, and WO16229.

We have reviewed your submission and conclude that the above commitment was fulfilled.

We remind you that there are postmarketing requirements and postmarketing commitments still open.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).
If you have any questions, contact Amy Tilley, Regulatory Project Manager, at (301) 796-3994 or amy.tilley@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Anthony J. Murgo, M.D., M.S.
Acting Director, Division of Oncology Products 1
Associate Office Director for Regulatory Science
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANTHONY J MURGO
11/20/2013